Survodutide is an investigational weekly injection that activates glucagon and GLP-1 receptors. Boehringer Ingelheim is developing it under license from Zealand Pharma for obesity and related metabolic diseases. Phase 3 findings are available, but positive trial results are not FDA approval or a basis for self-treatment.
The most useful way to read the results is to keep each trial, endpoint, and analysis separate. An earlier version of this page mixed findings from an obesity MRI substudy with the separate SYNCHRONIZE-MASLD trial and overstated comparative muscle and liver benefits. Those claims have been corrected.
How it differs from semaglutide and tirzepatide
Ozempic (semaglutide) and Wegovy (semaglutide) activate the GLP-1 receptor. Mounjaro (tirzepatide) and Zepbound (tirzepatide) activate GIP and GLP-1 receptors. Survodutide combines glucagon and GLP-1 receptor activity.
GLP-1 activity helps regulate appetite and glucose. Researchers are studying whether glucagon activity adds useful effects on liver fat and energy metabolism. A proposed mechanism does not establish that survodutide is safer or more effective than another medicine. The trials discussed below compared survodutide with placebo, not with semaglutide or tirzepatide.
Phase 2 weight-loss results
The 2024 phase 2 publication enrolled adults with BMI of at least 27 without diabetes. It studied 46 weeks of treatment, including a dose-escalation period. The planned-treatment analysis reported:
| Assigned study group | Average body-weight reduction at week 46 |
|---|---|
| Survodutide 0.6 mg | 6.2% |
| Survodutide 2.4 mg | 12.5% |
| Survodutide 3.6 mg | 13.2% |
| Survodutide 4.8 mg | 14.9% |
| Placebo | 2.8% |
These are experimental trial groups, not an approved dosing schedule or instructions for readers. The earlier table on this page incorrectly included a 7.2 mg group. Only about 60% of treated participants completed the 46-week treatment period, so the analysis method and missing-data assumptions matter. Headlines quoting approximately 19% should not be substituted for the planned-treatment result without explaining their different analysis.
SYNCHRONIZE-1: phase 3 obesity findings
In its June 2026 trial report, Boehringer described SYNCHRONIZE-1 as a 76-week trial in 725 adults with obesity or overweight without type 2 diabetes. The sponsor reported up to 16.6% average weight loss using the efficacy estimand, versus 3.2% with placebo. It identifies the main trial publication as being in the New England Journal of Medicine, not Nature Medicine.
An efficacy estimand estimates the effect under specified assumptions about remaining on treatment. A treatment-regimen estimand addresses treatment assignment regardless of discontinuation. Neither is a promise for an individual, and numbers from different estimands should not be ranked as though they measure the same thing.
The sponsor also reported an MRI substudy among participants with baseline and end-of-study measurements while on treatment:
- Up to 34.0% relative reduction in visceral fat.
- Up to 63.1% relative reduction in liver fat.
- Lean mass accounting for no more than 10.8% of the change in total tissue mass at the highest dose.
These are substudy findings, not the primary results of SYNCHRONIZE-MASLD. Lean mass is not identical to skeletal muscle or strength. This analysis does not establish better muscle preservation than other GLP-1 medicines, and it does not mean participants lost no lean tissue.
SYNCHRONIZE-MASLD: a separate liver-fat study
The peer-reviewed phase 3 report in Nature Medicine studied adults with obesity or overweight and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). Of 218 randomized participants, 216 received treatment. Some had type 2 diabetes. Follow-up was 48 weeks.
| Outcome | Efficacy estimand: survodutide vs placebo | Treatment-regimen estimand: survodutide vs placebo |
|---|---|---|
| Participants achieving at least 30% relative liver-fat reduction by MRI | 84.2% vs 24.3% | 68.5% vs 28.6% |
| Average body-weight reduction | 12.2% vs 1.0% | 8.7% vs 1.4% |
The first row describes the proportion reaching a threshold, not the average amount of liver fat lost. Liver-fat reduction and changes in noninvasive markers are not interchangeable with biopsy-proven MASH resolution, fibrosis reversal, or fewer cases of liver failure. The trial's duration and recruitment in the United States and Spain also limit what it can tell us about longer-term outcomes and other populations.
MASH, the inflammatory form of MASLD, is also being studied in the separate LIVERAGE program. Do not treat results from these programs as interchangeable. This page no longer claims survodutide is the first GLP-1-based approach to MASH; the Wegovy label already includes a specific MASH indication for its injection under accelerated approval.
Side effects and unresolved safety questions
In the phase 2 trial, gastrointestinal adverse events occurred in 75% of survodutide recipients versus 42% of placebo recipients. In the sponsor's SYNCHRONIZE-1 report, nausea, vomiting, diarrhea, and constipation were common, usually during escalation. Gastrointestinal adverse events led to treatment discontinuation in 19% of survodutide recipients versus 2.9% with placebo.
A description of events as mostly mild or moderate should not hide the number of people who stopped treatment. Nor does a sponsor's report of no new safety signal prove equal safety to an approved comparator. Longer follow-up and regulatory review are needed to characterize benefits and risks for any eventual indication.
Approval, access, and decisions now
Survodutide remains investigational in the sources reviewed for this update. Fast Track or Breakthrough Therapy designations support drug development; they do not authorize pharmacy sales. There is no confirmed approval date, retail price, insurance policy, or approved dose schedule to offer here.
For trial information, the registered studies include SYNCHRONIZE-1 and SYNCHRONIZE-MASLD. A study listing does not mean enrollment is open or that you qualify. The study team must confirm eligibility and explain risks, visits, and the possibility of placebo.
Do not buy products labeled "research use only" for personal treatment. If you need care now, discuss approved options appropriate to your diagnosis with a clinician rather than waiting for a predicted launch or planning an automatic switch. See our medication overview for the differences among existing treatments.
This article summarizes research and is not medical advice. Experimental trial doses are not prescribing instructions.
